«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 03

Page:

396-402

Research Field:

Publishing date:

Info

Title:

Differential expression analysis of serum exosomal miRNA in benign and malignant thyroid nodules with Hashimotos thyroiditis

Author(s):

QIAO Wenjing¹; WEI Xiangran²; YIN Fengyan³; ZHANG Hui⁴; CAO Wenyuan²; LUO Xiaoting²; HE Qian²; XING Hao³

1.Hematology Center,Qingdao University Affiliated Tai'an Central Hospital,Shandong Tai'an 271000,China;2.School of Public Health and Health Management,Shandong First Medical University,Shandong Jinan 250000,China;3.Department of Thyroid Surgery,Qingdao University Affiliated Tai'an Central Hospital,Shandong Tai'an 271000,China;4.Department of Laboratory Medicine,Qingdao University Affiliated Tai'an Central Hospital,Shandong Tai'an 271000,China.

Keywords:

papillary thyroid carcinoma; Hashimoto's thyroiditis; exosome; microRNA

PACS:

R736.1

DOI:

10.3969/j.issn.1672-4992.2025.03.006

Abstract:

Objective:To analyze the serum exosomal microRNA(miRNA) expression profiles of patients with papillary thyroid carcinoma (PTC) and benign thyroid nodules with and without Hashimotos thyroiditis(HT),and to provide a reference basis for the differentiation of the benign and malignant nature of thyroid nodules in clinical practice.Methods:Serum samples from patients with concomitant Hashimoto PTC,simple PTC,with Hashimoto's thyroid nodules,and simple thyroid nodules were selected,and exosomal miRNAs were extracted and subjected to high-throughput sequencing for the prediction of differentially expressed miRNAs and target genes,and then subjected to GO enrichment analysis and KEGG enrichment analysis.Results:In the concomitant Hashimoto group,there was a significant difference in the expression levels of 24 serum exosomal miRNAs between the PTC and compared with the benign group.In the unaccompanied Hashimoto group,there was a significant difference in the expression levels of 11 in the PTC and compared with the benign group.Combining the two groups,there was 1 common differentially expressed miRNA,miR-147b-3p,both of which were expressed in an upregulated manner.KEGG analysis showed that miR-147b-3p was enriched for either mitogen-activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K) signalling pathways,both of which are implicated in the development of PTC.Conclusion:With or without concomitant Hashimoto condition,there were differences in serum exosomal miRNA expression profiles between PTC and benign nodule groups.miR-147b-3p can be used for the diagnosis of benign and malignant thyroid nodules in both cases.

References:

［1］ 李斐，李舍予.全球甲状腺癌疾病负担［J］.中国全科医学，2018，21(26)：3155-3159. LI F,LI SY.Global disease burden of thyroid cancer［J］.Chinese Family Medicine,2018,21(26):3155-3159.
［2］ 苏未，顼禹同，王一诺，等.1990至2019年中国与全球甲状腺癌疾病负担比较分析［J］.中国医学科学院学报，2023，45(6)：940-948. SU W,XU YT,WANG YN,et al.Comparative analysis of the disease burden of thyroid cancer in China and the world from 1990 to 2019［J］.Journal of Chinese Academy of Medical Sciences,2023,45(6):940-948.
［3］ 谢哲，李一帆，王小祥，等.外泌体环状RNA在泌尿系统肿瘤中的研究进展［J］.生物化学与生物物理进展，2022，49(12)：2342-2354. XIE Z,LI YF,WANG XX,et al.Progress of exosomal cyclic RNA in urological tumors［J］.Advances in Biochemistry and Biophysics,2022,49(12):2342-2354.
［4］ THIND A,WILSON C.Exosomal miRNAs as cancer biomarkers and therapeutic targets［J］.J Extracell Vesicles,2016,5:31292.
［5］ ETHERIDGE A,LEE I,HOOD L,et al.Extracellular microRNA:a new source of biomarkers［J］.Mutat Res,2011,717(1-2):85-90.
［6］ MIN L,ZHU S,CHEN L,et al.Evaluation of circulating small extracellular vesicles derived miRNAs as biomarkers of early colon cancera comparison with plasma total miRNAs［J］.J Extracell Vesicles,2019,8(1):1643670.
［7］ DORRIS ER,SMYTH P,O' LEARY JJ,et al.MIR141 expression differentiates Hashimoto thyroiditis from PTC and benign thyrocytes in Irish archival thyroid tissues［J］.Front Endocrinol (Lausanne),2012,3:102.
［8］ 贾倩玉，张英霞.甲状腺癌分子标志物的研究现状［J］.现代肿瘤医学，2019，27（05）：902-905. JIA QY,ZHANG YX.Research status of molecular markers for thyroid cancer［J］.Modern Oncology,2019,27(05):902-905.
［9］ RALLI M,ANGELETTI D,FIORE M,et al.Hashimoto's thyroiditis:An update on pathogenic mechanisms,diagnostic protocols,therapeutic strategies,and potential malignant transformation［J］.Autoimmun Rev,2020,19(10):102649.
［10］ MCLEOD DS,COOPER DS.The incidence and prevalence of thyroid autoimmunity［J］.Endocrine,2012,42(2):252-265.
［11］ 刘新悦，赵鸿渐，邢浩，等.不同碘水平下血清外泌体miRNA的表达对甲状腺乳头状癌淋巴结转移的早期诊断价值［J］.现代肿瘤医学，2023，31(16)：3014-3018. LIU XY,ZHAO HJ,XING H,et al.Early diagnostic value of serum exosomal miRNA expression at different iodine levels for lymph node metastasiof papillary thyroid cancer［J］.Modern Oncology,2023,31(16):3014-3018.
［12］ 梁群秀，梁活富，刘玲.超声弹性成像及应变率比值在良恶性甲状腺结节体检中的应用［J］.现代医用影像学，2022，31（07）：1349-1352. LIANG QX,LIANG HF,LIU L.Application of ultrasound elastograph and strain rate ratio in physical examination of benign and malignant thyroid nodules［J］.Modern Medical Imaging,2022,31(07):1349-1352.
［13］ 李圣梅，薛从岚.分化型甲状腺癌病理特点及诊断方法研究［J］.中国卫生标准管理，2023，14（19）：103-106. LI SM,XUE CL.Study on the pathologic characteristics and diagnostic methods of differentiated thyroid cancer［J］.China Health Standard Management,2023,14(19):103-106.
［14］ 马秋晟.分子诊断甲状腺癌临床应用及靶向治疗新进展［J］.吉林医学，2023，44(06)：1599-1601. MA QS.Clinical application of molecular diagnosis of thyroid cancer and new progress of targeted therapy［J］.Jilin Med,2023,44(06):1599-1601.
［15］ 夏苇，张玉洪.分子诊断在甲状腺结节诊断中的应用和进展［J］.检验医学与临床，2021，18（08）：1163-1167. XIA W,ZHANG YH.Application and progress of molecular diagnosis in the diagnosis of thyroid nodules［J］.Laboratory Medicine and Clinics,2021,18(08):1163-1167.
［16］ 张秋雨，徐霞，颜建英.外泌体miRNA在妊娠期糖尿病发病中作用的研究进展［J］.中国计划生育和妇产科，2023，15（02）：36-38. ZHANG QY,XU X,YAN JY.Research progress on the role of exosoma miRNAs in the pathogenesis of gestational diabetes mellitus［J］.China Family Planning and Obstetrics and Gynecology,2023,15(02):36-38.
［17］ CHOU CK,LIU RT,KANG HY.miRNA-146b:A novel biomarker and therapeutic target for human papillary thyroid cancer［J］.Int J Mol Sci,2017,18(3):636.
［18］ PENG Y,LI C,LUO DC,et al.Expression profile and clinical significanceof miRNAs in papillary thyroid carcinoma［J］.Molecules,2014,19(8):11586-11599.
［19］ CATUREGLI P,DE REMIGIS A,ROSE NR.Hashimoto thyroiditis:clinical and diagnostic criteria［J］.Autoimmun Rev,2014,13(4-5):391-397.
［20］ XU J,DING K,MU L,et al.Hashimoto's thyroiditis:A "double-edged sword" in thyroid carcinoma［J］.Front Endocrinol (Lausanne),2022,13:801925.
［21］ 车勇军，连蕾，侯钰，等.miR-637在桥本甲状腺炎合并甲状腺乳头状癌患者组织穿刺标本中的水平变化及对甲状腺癌细胞增殖、侵袭的影响［J］.国际检验医学杂志，2022，43（13）：1593-1597. CHE YJ,LIAN L,HOU Y,et al.Changes in the levels of miR-637 in tissue puncture specimens from patients with Hashimoto's thyroiditis combined with papillary thyroid carcinoma and its effects on the proliferation and invasion of thyroid carcinoma cells［J］.International Journal of Laboratory Medicine,2022,43(13):1593-1597.
［22］ GAO T,ZHAO L,ZHANG F,et al.Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes,proteins,and immune factors［J］.World J Surg Oncol,2022,20(1):207.
［23］ HU N,TIAN Y,SONG Y,et al.miR-122-5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression［J］.Mol Med Rep,2021,23(5):368.
［24］ SHEN J,MA Z,YANG J,et al.CircPHGDH downregulation decreases papillary thyroid cancer progression through miR-122-5p/PKM2 axis［J］.BMC Cancer,2024,24(1):511.
［25］ 周亚萍，李翔，赵红梅，等.外泌体miRNA应用于甲状腺乳头状癌诊断的研究［J］.国际检验医学杂志，2022，43(11)：1295-1299. ZHOU YP,LI X,ZHAO HM,et al.Application of exosomal miRNA to the diagnosis of papillary thyroid carcinoma［J］.International Journal of Laboratory Medicine,2022,43(11):1295-1299.
［26］ TAO K,DONG JH,WANG D,et al.MIR-147b regulated proliferationand apoptosis of gastric cancer cells by targeting CPEB2 via the PTEN pathway［J］.Balkan J Med Genet,2023,25(1):61-70.
［27］ YI L,ZHONG X,CHEN Z,et al.miRNA-147b promotes proliferationand invasion of human colorectal cancer by targeting RAS oncogene family (RAP2B)［J］.Pathobiology,2019,86(4):173-181.
［28］ WANG G,MA Z,SONG C,et al.miR-147b is an oncomiR acting synergistically with HIPK2 to promote pancreatic carcinogenesis［J］.Cell Signal,2023,111:110840.
［29］ GIBRIEL AA,ISMAIL MF,SLEEM H,et al.Diagnosis and staging of HCV associated fibrosis,cirrhosis and hepatocellular carcinoma with target identification for miR-650,552-3p,676-3p,512-5p and 147b［J］.Cancer Biomark,2022,34(3):413-430.
［30］ NIKIFOROV YE,NIKIFOROVA MN.Molecular genetics and diagnosis of thyroid cancer［J］.Nat Rev Endocrinol,2011,7(10):569-580.
［31］ ZHAN S,WANG T,LI J,et al.Asporin interacts with HER2 to promote thyroid cancer metastasis via the MAPK/EMT signaling pathway［J］.Front Oncol,2022,12:762180.
［32］ YE K,LI J,LI X,et al.Ang1/Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K/AKT pathway［J］.Oncol Lett,2018,15(1):1313-1318.
［33］ XU J,CAI J,JIN X,et al.PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway［J］.Oncol Rep,2015,34(3):1424-1430.

Memo

Memo:

山东省自然科学基金（编号：ZR2023QH135）；山东省泰安市科技创新课题（编号：2022NS234）

Common functions

Last Update: 1900-01-01